(Albany, US) DelveInsight launched a new report on Fragile X Syndrome Market Insights, Epidemiology and Market Forecast-2030
Some of the key facts of the report– The total cases of Fragile X Syndrome in the 7MM was found to be 117,962 in 2017.– Among all the countries, the highest population of Fragile X Syndrome was in the United States with 67,654 cases in 2017.– Among the EU5 countries, Germany had the highest diagnosed Fragile X Syndrome prevalent population with 9,383 cases, followed by France.
Key benefits of the report1. Fragile X Syndrome market report covers a descriptive overview and comprehensive insight of the Fragile X Syndrome epidemiology and Fragile X Syndrome market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)2. Fragile X Syndrome market report provides insights into the current and emerging therapies.3. Fragile X Syndrome market report provides a global historical and forecasted market covering drug outreach in 7 MM.4. Fragile X Syndrome market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Fragile X Syndrome market.
Request for sample pages
“There were 40,102 cases of Fragile X Syndrome in males and 27,552 prevalent cases in females in the US in 2017.”
Currently, there is no FDA-approved treatment for Fragile X Syndrome. The treatment relies on the associated symptoms of Fragile X Syndrome which are typically managed using pharmacologic interventions, such as stimulants for attention deficit and hyperactivity, selective serotonin reuptake inhibitors (SSRIs) for anxiety, antipsychotic drugs for aggression and mood instability, and melatonin for sleep.
In boys with Fragile X Syndrome, the most frequently used medications are stimulants. These medications are targeted toward the symptoms of hyperactivity, impulsivity, and distractability and can be quite helpful in these areas. Despite being the most common medication in Fragile X Syndrome, the efficacy of these drugs and their side effects vary for each individual.
Selective serotonin reuptake inhibitors (SSRIs) are used to treat mood disorder, anxiety, and obsessive-compulsive behaviours associated with FXS. They are useful, particularly in alleviating social anxiety, tantrums, and aggression. Fluoxetine can be beneficial for selective mutism.
The launch of the emerging therapies is expected to significantly impact Fragile X Syndrome treatment scenario in the upcoming years:-Drugs covered1. Cannabidiol2. Acamprosate3. BPN147704. OV1015. TrofinetideAnd many others
The key players in Fragile X Syndrome market are:1. Zynerba Pharmaceuticals2. Confluence Pharmaceuticals3. Tetra Therapeutics4. Ovid Therapeutics5. Neuren PharmaceuticalsAnd many others
Table of contents1. Key Insights2. Executive summary3. Organisations4. Fragile X Syndrome Epidemiology and Market Methodology5. Fragile X Syndrome Market Overview at a Glance6. Fragile X Syndrome Disease Background and Overview7. Fragile X Syndrome Epidemiology and Patient Population7.1. Key Findings7.2. Total Diagnosed Prevalent cases of Fragile X Syndrome in 7MM7.3. United States7.4. EU57.5. Assumptions and Rationale7.6. Germany7.7. France7.8. Italy7.9. Spain7.10. United Kingdom (UK)7.11. Japan8. Fragile X Syndrome Current Treatment9. Unmet Need10. Fragile X Syndrome Emerging Drugs10.1. Key Cross Competition10.2. Cannabidiol: Zynerba Pharmaceuticals10.3. Acamprosate: Confluence Pharmaceuticals10.4. BPN14770: Tetra Therapeutics10.5. OV101: Ovid Therapeutics10.6. Trofinetide: Neuren Pharmaceuticals11. Fragile X Syndrome Market Size12. Fragile X Syndrome Market Outlook: 7 MM12.1. United States12.2. EU512.3. Germany12.4. France12.4.3. Italy12.5. Spain12.6. United Kingdom12.7. Japan13. Market Drivers14. Market Barriers15. SWOT analysis16. Cases studies17. KOL Views18. Appendix19. DelveInsight Capabilities20. Disclaimer21. About DelveInsight
About DelveInsightDelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Media ContactCompany Name: DelveInsightContact Person: Priya MauryaEmail: Send EmailPhone: +919650213330City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/